One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Camatinib is an oral inhibitor of the oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)), with potential anti-tumor activity. Camatinib selectively binds to c-Met, thereby inhibiting its phosphorylation and disrupting the signal transduction pathway of c-Met. C-Met is a receptor tyrosine kinase that is overexpressed or mutated in many types of tumor cells, playing a crucial role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
One year of qualification
Audited Supplier
Pharma Sources Insight January 2025
![(1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride](https://eimg.pharmasources.com/image/product/20231221/3fcbabc678d316944d906bace0e06634jpg!145)
